| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
|
JAMA
|
2008
|
7.07
|
|
2
|
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.
|
J Clin Oncol
|
2008
|
2.81
|
|
3
|
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
|
Int J Radiat Oncol Biol Phys
|
2011
|
2.54
|
|
4
|
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
|
Ann Surg Oncol
|
2011
|
2.38
|
|
5
|
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
|
J Clin Oncol
|
2011
|
2.24
|
|
6
|
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
|
Int J Radiat Oncol Biol Phys
|
2012
|
2.12
|
|
7
|
ErbB2 degradation mediated by the co-chaperone protein CHIP.
|
J Biol Chem
|
2003
|
1.70
|
|
8
|
Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial.
|
Cancer
|
2010
|
1.40
|
|
9
|
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
|
J Clin Oncol
|
2009
|
1.33
|
|
10
|
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.
|
Cancer Invest
|
2004
|
1.33
|
|
11
|
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.08
|
|
12
|
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
|
J Gastrointest Surg
|
2012
|
1.06
|
|
13
|
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.05
|
|
14
|
Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
|
Am J Clin Oncol
|
2006
|
1.04
|
|
15
|
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
|
Am J Clin Oncol
|
2005
|
1.02
|
|
16
|
Cellular immunotherapy for refractory hematological malignancies.
|
J Transl Med
|
2013
|
0.99
|
|
17
|
Combined modality therapy for pancreatic cancer.
|
Semin Oncol
|
2003
|
0.95
|
|
18
|
Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
|
Am J Clin Oncol
|
2017
|
0.93
|
|
19
|
Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma.
|
Pancreas
|
2002
|
0.88
|
|
20
|
Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
|
Am J Clin Oncol
|
2012
|
0.87
|
|
21
|
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
|
Am J Clin Oncol
|
2014
|
0.87
|
|
22
|
Paclitaxel and concurrent radiation in upper gastrointestinal cancers.
|
Cancer Invest
|
2003
|
0.86
|
|
23
|
Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.
|
J Hepatol
|
2012
|
0.85
|
|
24
|
Status of treatment for advanced gastric carcinoma.
|
Curr Oncol Rep
|
2003
|
0.84
|
|
25
|
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling.
|
Am J Surg Pathol
|
2015
|
0.82
|
|
26
|
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
|
Am J Clin Oncol
|
2011
|
0.82
|
|
27
|
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
|
Onco Targets Ther
|
2012
|
0.82
|
|
28
|
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
|
Am J Clin Oncol
|
2007
|
0.82
|
|
29
|
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
|
Am J Clin Oncol
|
2005
|
0.81
|
|
30
|
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
|
Cancer Invest
|
2007
|
0.81
|
|
31
|
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
|
Clin Cancer Res
|
2009
|
0.80
|
|
32
|
Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study.
|
Am J Clin Oncol
|
2010
|
0.80
|
|
33
|
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.80
|
|
34
|
A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone.
|
Cancer
|
2002
|
0.79
|
|
35
|
Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer.
|
Front Oncol
|
2012
|
0.79
|
|
36
|
Nonengraftment haploidentical cellular therapy for hematologic malignancies.
|
Adv Hematol
|
2012
|
0.78
|
|
37
|
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.
|
Front Oncol
|
2012
|
0.78
|
|
38
|
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
|
Am J Clin Oncol
|
2010
|
0.78
|
|
39
|
Multimodality treatment of esophageal cancer: a review of the current status and future directions.
|
Curr Oncol Rep
|
2006
|
0.77
|
|
40
|
A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma.
|
Cancer
|
2002
|
0.77
|
|
41
|
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
|
Am J Clin Oncol
|
2017
|
0.76
|
|
42
|
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
|
Cancer Med
|
2014
|
0.76
|
|
43
|
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
|
Am J Clin Oncol
|
2015
|
0.76
|
|
44
|
HER family inhibitors in pancreatic cancer: current status and future directions.
|
Expert Opin Ther Targets
|
2007
|
0.76
|
|
45
|
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.75
|
|
46
|
Evaluation and treatment of hepatic metastases from unknown GI primary.
|
Med Health R I
|
2002
|
0.75
|
|
47
|
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study.
|
Am J Clin Oncol
|
2014
|
0.75
|
|
48
|
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
|
Cancer
|
2006
|
0.75
|
|
49
|
Chemotherapy for pancreatic cancer.
|
Med Health R I
|
2004
|
0.75
|